Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more

Recent & Breaking News (NDAQ:AUTL)

Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

GlobeNewswire November 3, 2022

Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress

GlobeNewswire November 3, 2022

Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022

GlobeNewswire October 21, 2022

Moderna exercises option to license proprietary targeting technology from Autolus

GlobeNewswire October 12, 2022

Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System

GlobeNewswire October 4, 2022

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

GlobeNewswire September 20, 2022

Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress

GlobeNewswire August 4, 2022

Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 21, 2022

Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 21, 2022

Autolus Therapeutics to Participate in William Blair's Biotech Focus Conference 2022, New York, July 12 - 13, 2022

GlobeNewswire July 6, 2022

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

GlobeNewswire June 10, 2022

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022

GlobeNewswire May 31, 2022

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 - 10, 2022

GlobeNewswire May 27, 2022

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

GlobeNewswire May 12, 2022

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

GlobeNewswire May 5, 2022

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022 

GlobeNewswire May 2, 2022

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

GlobeNewswire April 25, 2022

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

GlobeNewswire April 25, 2022

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

GlobeNewswire March 31, 2022

Autolus Therapeutics to Participate in Conferences During April 2022

GlobeNewswire March 29, 2022